SHARE-BASED PAYMENTS TO VENDORS (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |
---|---|---|---|
Oct. 31, 2019 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
Granted | 2,357,500 | ||
General and Administrative | $ 10,784,023 | $ 2,397,059 | |
Research and Development | $ 2,030,177 | 2,202,979 | |
Fair value of share granted | $ 4.72 | ||
Share Based Payments To Vendor | |||
General and Administrative | $ 201,375 | 338,802 | |
Research and Development | $ 21,596 | $ 233,311 | |
Members' Equity, Class A | |||
Granted | 150,000 | 30,145 | 147,413 |
Fair value of share granted | $ 2.00 |
X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. No definition available.
|
X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|